OR WAIT null SECS
October 14, 2010
On Tuesday, Pfizer (New York) and King Pharmaceuticals (Bristol, TN), a specialty pharmaceutical-discovery and clinical-development company, entered into a definitive merger agreement under which Pfizer will acquire King for $3.6 billion in cash, or $14.25 per share.
October 07, 2010
Company and People Notes: Novartis Settles with US Attorney's Office; Hospira Names VP, And More.
October 02, 2010
The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.
The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.
From disagreement to denial, being cordial about quality control can be challenging.
In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.
The authors developed a formulation for effervescent gastroretentive drug delivery techniques using ibuprofen as a model drug. They optimized the formulations by applying full factorial design.
October 01, 2010
The authors review and discuss the influence of glycans on the conformation of a representative IgG1 biopharmceutical using H/DX-MS as an analytical tool.
September 30, 2010
Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.
September 23, 2010
DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.